Cross-Sector entity
All 1 tracked stories fall under one category: regulation. Australasian Menopause Society is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Claire, all published on February 27, 2026.
1 verified story tracked
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Australasian Menopause Society is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Claire, all published on February 27, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Claire. Shared-story counts are live from our verified record — not editorial picks.
Public Advocacy Surge
Increased media coverage and patient advocacy highlight the pricing disparity between genders.
TGA Approval
The Therapeutic Goods Administration approves the first female-specific testosterone cream.
Global Consensus Statement
International medical societies reach consensus on testosterone use for women's sexual health.
Australian women are facing significant financial barriers to accessing testosterone therapy, often paying substantially more than men for the same hormone treatment. While the therapy is clinically recognized for treating sexual dysfunction in postmenopausal women, the lack of subsidized options highlights a systemic gap in the national pharmaceutical framework.
Source: theage.com.au · brisbanetimes.com.au
